Blockers of Angiotensin Other Than Olmesartan in Patients With Villous Atrophy: A Nationwide Case-Control Study

Ludvigsson, 2013, The Oslo definitions for coeliac disease and related terms, Gut, 62, 43, 10.1136/gutjnl-2011-301346 Walker, 2010, Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study, Gastroenterology, 139, 112, 10.1053/j.gastro.2010.04.007 Dewar, 2005, Clinical features and diagnosis of celiac disease, Gastroenterology, 128, S19, 10.1053/j.gastro.2005.02.010 Rubio-Tapia, 2012, Severe spruelike enteropathy associated with olmesartan, Mayo Clin Proc, 87, 732, 10.1016/j.mayocp.2012.06.003 Greywoode, 2014, Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study, Mayo Clin Proc, 89, 1239, 10.1016/j.mayocp.2014.05.012 Menne, 2012, Olmesartan and intestinal adverse effects in the ROADMAP study, Mayo Clin Proc, 87, 1230, 10.1016/j.mayocp.2012.10.005 Ianiro, 2014, Systematic review: sprue-like enteropathy associated with olmesartan, Aliment Pharmacol Ther, 40, 16, 10.1111/apt.12780 Bhat, 2014, Olmesartan-related sprue-like enteropathy, Indian J Gastroenterol, 33, 564, 10.1007/s12664-014-0506-7 Marthey, 2014, Olmesartan-associated enteropathy: results of a national survey, Aliment Pharmacol Ther, 40, 1103, 10.1111/apt.12937 Ludvigsson, 2009, Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers, BMC Gastroenterol, 9, 19, 10.1186/1471-230X-9-19 Marsh, 1990, Grains of truth: evolutionary changes in small intestinal mucosa in response to environmental antigen challenge, Gut, 31, 111, 10.1136/gut.31.1.111 Ludvigsson, 2009, The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research, Eur J Epidemiol, 24, 659, 10.1007/s10654-009-9350-y Ludvigsson, 2009, Symptoms and signs in individuals with serology positive for celiac disease but normal mucosa, BMC Gastroenterol, 9, 57, 10.1186/1471-230X-9-57 Ludvigsson, 2009, Small-intestinal histopathology and mortality risk in celiac disease, JAMA, 302, 1171, 10.1001/jama.2009.1320 Wettermark, 2007, The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months, Pharmacoepidemiol Drug Saf, 16, 726, 10.1002/pds.1294 Rothman, 2008 Statistics Sweden. Statistical database. www.socialstyrelsen.se/statistik/statistikdatabas. Accessed December 2, 2014. Weitoft, 2008, Education and drug use in Sweden—a nationwide register-based study, Pharmacoepidemiol Drug Saf, 17, 1020, 10.1002/pds.1635 Westin, 2004, A large proportion of Swedish citizens refrain from seeking medical care—lack of confidence in the medical services a plausible explanation?, Health Policy, 68, 333, 10.1016/j.healthpol.2003.10.008 Herman, 2015, A case of severe sprue-like enteropathy associated with valsartan, ACG Case Rep J, 2, 92, 10.14309/crj.2015.15 Emilsson, 2013, The characterisation and risk factors of ischaemic heart disease in patients with coeliac disease, Aliment Pharmacol Ther, 37, 905, 10.1111/apt.12271 Cyrany, 2014, Letter: telmisartan-associated enteropathy—is there any class effect?, Aliment Pharmacol Ther, 40, 569, 10.1111/apt.12850 Lagana, 2015, Sprue-like histology in patients with abdominal pain taking olmesartan compared with other angiotensin receptor blockers, J Clin Pathol, 68, 29, 10.1136/jclinpath-2014-202615 DeGaetani, 2013, Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma, Am J Gastroenterol, 108, 647, 10.1038/ajg.2013.45 West, 2004, Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study, Aliment Pharmacol Ther, 20, 73, 10.1111/j.1365-2036.2004.02008.x